New York State Teachers Retirement System Has $37.31 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

New York State Teachers Retirement System reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 176,458 shares of the medical research company’s stock after selling 5,358 shares during the period. New York State Teachers Retirement System owned approximately 0.10% of IQVIA worth $37,310,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its stake in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in IQVIA in the second quarter worth $27,000. Rise Advisors LLC acquired a new position in IQVIA in the first quarter worth $31,000. Riverview Trust Co acquired a new position in IQVIA in the first quarter worth $32,000. Finally, Covestor Ltd boosted its stake in IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after purchasing an additional 48 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Up 1.4 %

IQV stock traded up $3.43 during midday trading on Friday, hitting $248.39. The company’s stock had a trading volume of 269,865 shares, compared to its average volume of 1,064,177. The company has a market cap of $45.28 billion, a PE ratio of 33.93, a P/E/G ratio of 2.26 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The firm’s 50-day moving average is $227.07 and its 200-day moving average is $232.80. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. IQVIA’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.22 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on IQV. Barclays boosted their price objective on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. UBS Group boosted their target price on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. JPMorgan Chase & Co. boosted their target price on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Argus upgraded IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Robert W. Baird upped their price objective on IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $265.67.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.